ASP6918

Cat. No.:	HY-162249
Molecular Formula:	$C_{36}H_{43}N_7O_3$
Molecular Weight:	621.77
Target:	Ras
Pathway:	GPCR/G Protein; MAPK/ERK Pathway
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ASP6918 is a potent and orally active KRAS G12C inhibitor with an IC_{50} value of 0.028 μM. ASP6918 inhibits cell growth. ASP6918 shows antitumor activity[1].
IC_{50} & Target	KRas G12C 0.028 μM (IC_{50})

In Vitro

ASP6918 (compound 29a) (6 days) inhibits cell growth with an IC_{50} value of 0.0061 μM for NCI-H1373 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	NCI-H1373 cells
Concentration:	
Incubation Time:	6 days
Result:	Inhibited cell growth with an IC_{50} value of 0.0061 μM.

In Vivo

ASP6918 (10, 20, 40, 60 mg/kg; p.o.; daily for 13 days) shows antitumor activity in NCI-H1373 xenograft mouse model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Four-week-old male nude mice (NCI-H1373 xenograft mouse model)[1]
Dosage:	10, 20, 40, 60 mg/kg
Administration:	Oral, daily for 13 days
Result:	Inhibited of tumor growth with tumor growth inhibition (TGI) rate of 27%, 68%, 49%, 73% at 10, 20, 40, 60 mg/kg.

REFERENCES

[1]. Imaizumi T, et al. Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors. Bioorg Med Chem. 2024 Jan 15;98:117581.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA